Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Oncothyreon Inc. (ONTY - Snapshot Report) announced that Merck KGaA (MKGAF) has decided to continue with the development of its oncology candidate L-BLP25 (tecemotide; previously known as Stimuvax). Merck KGaA will conduct the phase III START2 study in patients with locally advanced stage III non-small cell lung cancer (NSCLC).

Merck KGaA had in-licensed worldwide exclusive rights to L-BLP25 from Oncothyreon.

L-BLP25 had failed to meet its primary endpoint of overall survival in the multi-center, randomized, double-blind, placebo-controlled START study conducted in patients with locally advanced stage III NSCLC. However, treatment effects were seen in certain subgroups. In a predefined subgroup of patients who received concurrent chemoradiotherapy (CRT), the median overall survival was 30.8 months in the L-BLP25 arm compared with 20.6 months for placebo. This prompted Merck KGaA to initiate the START2 study.

The phase III, multicenter, randomized, double-blind, placebo-controlled, START2 study will evaluate the efficacy, safety and tolerability of L-BLP25 in patients with unresectable, locally advanced NSCLC who have either responded to or shown stable disease after at least two cycles of platinum-based concurrent CRT.

For this study, Merck KGaA has received scientific advice from the European Medicines Agency (EMA) and has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA).

Currently, a second phase III trial, INSPIRE, is being conducted with L-BLP25. The trial is evaluating L-BLP25 in Asian patients suffering from unresectable, stage IIIA or IIIB NSCLC who have either responded to or shown stable disease after at least two cycles of platinum-based CRT. Enrolment is currently in progress.

Oncothyreon carries a Zacks Rank #3 (Hold). Companies which look attractive include Actelion Ltd. (ALIOF) and Affymetrix Inc. (AFFX - Analyst Report), each with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%